Share this article
Results Provide New Evidence of the Recommended Formula Determined in the AREDS2 Study
LAVAL, Quebec, May 11, 2021 /PRNewswire/ Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health ), today announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help reduce the risk of progression in patients with moderate to advanced Age-Related Macular Degeneration (AMD).
1 That formula is currently found in
Press release content from Business Wire. The AP news staff was not involved in its creation.
Global Oral Biologics Market to Surpass US$ 11,907.2 Million by 2028, Says Coherent Market Insights (CMI)
May 7, 2021 GMT
SEATTLE (BUSINESS WIRE) May 7, 2021
According to Coherent Market Insights, the global oral biologics market is estimated to be valued at
US$ 1,437.4 million in
2021 and is expected to exhibit a
CAGR of
(2021-2028).
Key Trends and Analysis of the Global Oral Biologics Market:
Key players are focused on strategies such as fund raising to boost their research and development of oral biologics for treatment of various chronic diseases such as diabetes, inflammatory bowel diseases, and others, which is expected to drive the market growth.
Research into octopus vision leads to a quick and easy test for incurable sight loss
University of Bristol research into octopus vision has led to a quick and easy test that helps optometrists identify people who are at greater risk of macular degeneration, the leading cause of incurable sight loss.
The basis for this breakthrough was published in the latest issue of the
Journal of Experimental Biology and describes new technology developed by lead researcher, Professor Shelby Temple, to measure how well octopus- which are color-blind - could detect polarized light, an aspect of light that humans can t readily see. Using this novel technology, the research team showed that octopus have the most sensitive polarization vision system of any animal tested to date. Subsequent research used the same technology in humans and led to the development of a novel medical device that assesses the risk factor for sight loss later in life.
Home / Top News / Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
AC – Inflammation was Mild and Decreasing over Time in Cohort 3
AC – Inflammation was Mild and Decreasing over Time in Cohort 3
VC – Inflammation was Mild and Decreasing over Time in Cohort 3
VC – Inflammation was Mild and Decreasing over Time in Cohort 3
Steroid Eye Drops Post Prophylaxis Decrease over Time in Cohort 3
Steroid Eye Drops Post Prophylaxis Decrease over Time in Cohort 3